Trial Profile
Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd; Eisai Inc
- 24 May 2016 According to Eisai media release, final analysis results of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
- 26 Aug 2015 Results (n=59) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.